88. Chronic thromboembolic pulmonary hypertension Clinical trials / Disease details
Clinical trials : 157 / Drugs : 107 - (DrugBank : 22) / Drug target genes : 14 - Drug target pathways : 54
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05179356 (ClinicalTrials.gov) | January 1, 2023 | 16/12/2021 | Dapagliflozin in Pulmonary Arterial Hypertension | Effects of DAPAgliflozin on Cardiopulmonary Exercise Capacity and Hemodynamics in Pulmonary Arterial Hypertension: A Double Blind Randomized Trial. (DAPAH-trial) | Pulmonary Arterial Hypertension;Chronic Thromboembolic Pulmonary Hypertension | Drug: Dapagliflozin 10 MG [Farxiga];Drug: Placebo | Mads Ersbøll | NULL | Not yet recruiting | 18 Years | N/A | All | 52 | Phase 2 | NULL |